(Q38169212)

30 August 2017

title

Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches (English)

1 reference

30 August 2017

0 references

J A Mikulca

1

1 reference

30 August 2017

V Nguyen

2

1 reference

30 August 2017

D A Gajdosik

3

1 reference

30 August 2017

S G Teklu

4

1 reference

30 August 2017

E A Giunta

5

1 reference

30 August 2017

E A Lessa

6

1 reference

30 August 2017

C H Tran

7

1 reference

30 August 2017

E C Terak

8

1 reference

30 August 2017

R B Raffa

9

1 reference

30 August 2017

publication date

8 December 2013

1 reference

Journal of Clinical Pharmacy and Therapeutics

30 August 2017

published in

1 reference

30 August 2017

volume

39

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

25-37

1 reference

Potential novel targets for Alzheimer pharmacotherapy: I. Secretases

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

gamma-secretase as a therapeutic target for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Sting of Alzheimer's failures offset by upcoming prevention trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Identification of BACE2 as an avid ß-amyloid-degrading protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Patterns of brain activation in people at risk for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Combination therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Clinical and research diagnostic criteria for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

Immunotherapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12112

21 January 2018

Identifiers

DOI

10.1111/JCPT.12112

1 reference

release_fzsaum3ynnbnrotzcspzn3q5se

30 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fzsaum3ynnbnrotzcspzn3q5se

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference